在药物设计中AlphaFold的起
Adrian Stecula1, Rebecca Paul1, Kevin Litchfield1
1Isomorphic Labs, London, United Kingdom.
Progress in medicinal chemistry
|October 23, 2025
概括
人工智能 (AI) 正在彻底改变药物设计,从目标识别到基于结构的药物设计. 人工智能驱动的结构生物学进步有望更快地开发精确的新疗法.
科学领域:
- 结构生物学是结构生物学.
- 人工智能的人工智能是人工智能.
- 药物发现 药物发现
背景情况:
- AlphaFold已经开启了结构生物学的一个新时代.
- 人工智能技术正在显著影响药物设计过程.
研究的目的:
- 讨论人工智能驱动药物设计的进展.
- 探索AI在目标识别,虚拟查和基于结构的药物设计中的作用.
- 检查诸如蛋白质-蛋白质相互作用调制和分子等边界.
主要方法:
- 在药物设计中对人工智能应用的审查.
- 讨论基于结构的药物设计原则.
- 在抗体药物设计中探索AI.
主要成果:
- 人工智能加快了打击寻找活动,并使基于结构的药物设计成为可能.
- 人工智能促进了分子和抗体设计的理性发现.
- 人工智能增强了对治疗开发的生物机制的理解.
结论:
- 人工智能驱动的结构洞察力正在改变药物设计.
- 新的治疗方法可以以前所未有的精度和速度设计.
- 人工智能模型在药物设计中的当前局限性得到了承认.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K
Protein Folding
126.2K
Overview
126.2K
Conserved Binding Sites
5.0K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
5.0K
Drug-Receptor Bonds
4.2K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
4.2K
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K


